key: cord-1017276-eyr00ey5
authors: Jia, Na; Zeng, Ping; Xia, Jun; Liu, Deping
title: Impact of more variations on in‐hospital mortality among patients with confirmed COVID‐19
date: 2022-03-21
journal: J Clin Hypertens (Greenwich)
DOI: 10.1111/jch.14472
sha: fa7c8c35ebd30c0bee02c157c4d2460bb77cb336
doc_id: 1017276
cord_uid: eyr00ey5

nan

Thanks for Aftab and co-authors' feedback on this systematic review.

Three questions were raised in their letter. We tried to respond to the best of our knowledge, in this letter. Question 1. In-hospital mortality rates decreased in the US over 2020. A retrospective analysis during this time period would be strengthened by accounting for the variation.

Response: Several factors may influence mortality rate, for example, optimized treatment plan, viral toxicity attenuation and so on.

Most of the included studies in our systematic review were carried out in early stage of the global pandemic (i.e., up to June 2020) in hospital setting with inpatients, thus we were unable to make infer- Response: We suggest to look at the impact of this from the angles of in-hospital mortality and mortality in community settings.

We agree with Aftab and co-authors that in-hospital mortality may be impacted by socioeconomic and sociocultural factors. The in-hospital mortality rate varied between 7% and 30% 1-5 across different countries. Tereshchenko's study 6 While we also agree with Aftab and co-authors that socioeconomic and sociocultural variation may alter the risk of mortality in general (beyond hospital setting), this is an epidemiological investigation which is beyond the scope of our study (which focuses on in-hospital outcomes). Question 3. Continuation or discontinuation of the ACEI/ARB after discharge from the hospital was not controlled.

Response: Aftab and co-authors highlighted an important issue. This was taken into account in our protocol design. We planned to do subgroup analysis on continuation versus discontinuation of ACEI/ARB, but we had only a single randomized control trial (NCT04338009) included in the review, hence were unable to carry out subgroup analysis. The single RCT showed that the mortality rate between discontinuation and continuation of ACEI/ARB was 12.99% versus 14.67%, which is higher than the finding from the Brazil study. 7 This could be resulted by varied disease severity and existing comorbidities, but we are not sure.

In conclusion, we thank Aftab and co-authors for their thoughtprovoking feedback. In general, we agree that these are important confounding issues which begs for further investigation, should data becomes available in future updates.

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) are protective against ICU admission and mortality for patients with COVID-19 disease

Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis

Association Between baseline use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19

Impact of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in hypertensive patients with COVID-19 (COVIDECA Study)

Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension

Rate of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers use and the number of COVID-19-confirmed cases and deaths

Effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted With COVID-19: a randomized clinical trial